Alpha 9 integrin in spinal cord repair: a critical appraisal of mechanisms, circuitry, and translational potential

Abstract

In response to the groundbreaking study by Stepankova et al. (Acta Neuropathol Commun 13:89, 2025) demonstrating that activated α9 integrin enables sensory axon regeneration after spinal cord injury, this letter provides a critical perspective on the mechanistic underpinnings and translational implications of their findings. While acknowledging the significance of identifying α9 integrin as a potent pro-regenerative driver, we highlight several areas requiring deeper investigation. Specifically, we interrogate the precise ligand-receptor interactions within the inhibitory injury environment and potential crosstalk with inhibitory signaling pathways. Furthermore, we raise critical concerns regarding the long-term stability and functional specificity of the regenerated sensory circuits, emphasizing the risk of maladaptive synaptogenesis leading to neuropathic pain. Finally, we contextualize these findings within the challenges of clinical translation, arguing that the efficacy of this approach must be validated in more severe, contusive injury models that better recapitulate the human pathology. This critical analysis aims to frame the essential next steps required to transform this compelling biological discovery into a viable therapeutic strategy.

To the Editor,

We read with considerable interest the seminal work by Stepankova et al. [1] demonstrating that targeted activation of α9 integrin in sensory neurons promotes robust axonal regeneration and sensory functional recovery after dorsal root crush. While this study represents a paradigm shift in targeting adhesion molecules for neural repair, a deeper mechanistic and translational critique is warranted to contextualize its findings and guide future research.

A primary outstanding question concerns the precise molecular logic of α9 integrin signaling within the inhibitory CNS environment. The authors posit tenascin-C (TNC) as a likely ligand [1]. However, TNC exhibits contextual duality—its pro-regenerative effects in development contrast sharply with its scar-associated inhibitory role post-injury [2]. Does activated α9 integrin engage a specific pro-regenerative TNC isoform or splice variant? Furthermore, integrin signaling crosstalk is complex. The observed phenotype could result from trans-dominant inhibition of other integrin heterodimers that convey inhibitory signals from glial scar components like chondroitin sulfate proteoglycans (CSPGs) [3]. A critical experiment would involve culturing α9-integringag neurons on substrates of purified TNC versus CSPGs, and utilizing specific pathway inhibitors (e.g., against Kindlin-1 or Src family kinases) to dissect whether this is a purely pro-growth signaling event or a concurrent blockade of inhibitory cascades.

Secondly, the long-term stability and functional integrity of the regenerated circuitry remain unproven. The reported recovery at 8 weeks post-injury is compelling, but the mammalian CNS is prone to subsequent axon pruning and synaptic destabilization [4]. Will these newly formed connections, which likely bypass traditional developmental checkpoints, be maintained over 6 or 12 months? More importantly, the potential for maladaptive synaptogenesis is a significant concern. Ectopic sensory reinnervation could precipitate neuropathic pain or autonomic dysreflexia—common and debilitating sequelae of SCI. The study would be greatly strengthened by long-term experiments employing conditional tracing of the regenerated axons and detailed electrophysiological assessments to determine if sensory inputs are correctly mapped and if dorsal horn interneuron networks process this information normally, or if aberrant circuits underlie the behavioral recovery.

Finally, the translational leap to a clinically relevant SCI model presents a formidable challenge. The dorsal root crush model, while clean for assessing primary sensory axon regeneration, does not recapitulate the cystic cavitation, mixed motor/sensory damage, and intense neuroinflammation of a human contusive SCI [5]. It is uncertain if α9 integrin-activated axons can penetrate and navigate a lesion core filled with macrophages and fibrotic scar. A critical next step is to test this strategy in a severe contusion model. The AAV delivery approach to DRGs is clinically feasible, yet the oncogenic potential of sustained, constitutive integrin activation must be thoroughly evaluated. A conditional system that allows for temporal control of the transgene expression would be a prudent safety feature for any future therapeutic development.

In summary, Stepankova et al. have identified a potent molecular lever for axon regeneration [1]. The true impact of this work will be determined by resolving the nuanced mechanisms of α9 integrin action, ensuring the newly formed circuits are both stable and precise, and demonstrating efficacy in a therapeutically relevant injury paradigm. The path forward is challenging but holds immense promise for restorative neurology.

Sincerely,

Author contributions

YDJ, QLS: conceptualization, Methodology, Writing—Original Draft Preparation, Supervision. GQW: data Curation, Formal Analysis, Investigation, Visualization. CB: validation, Resources, Writing—Review & Editing. LDD: project Administration, Funding Acquisition, Supervision. All authors have read and agreed to the final version of the manuscript.

Funding

Not Applicable.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not Applicable.

Consent for publication

Not Applicable.

Competing interests

All authors have no conflicts of interest or financial ties to disclose.